Profile data is unavailable for this security.
About the company
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Pharma Nigeria Ltd., Trophic Wellness Pvt. Ltd.
- Revenue in INR (TTM)77.07bn
- Net income in INR5.47bn
- Incorporated1949
- Employees16.17k
- LocationIPCA Laboratories Ltd125,Kandivli Industrial Estate, Kandivli (WeMUMBAI 400067IndiaIND
- Phone+91 2 262105000
- Fax+91 2 228686613
- Websitehttps://www.ipca.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi India Ltd | 28.47bn | 5.49bn | 151.49bn | 2.17k | 27.59 | -- | 25.72 | 5.32 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 172.39bn | 947.00 | 106.75 | 24.22 | 97.70 | 13.31 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 176.14bn | 1.38k | 57.19 | 11.54 | 48.70 | 17.32 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 194.41bn | 14.86k | 31.56 | 4.03 | 21.88 | 3.12 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | 4,192,105.00 | 9.75 | 10.72 | 12.92 | 14.25 | 72.46 | 65.98 | 9.89 | 12.47 | 0.9863 | 11.56 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 207.11bn | 1.17k | 68.89 | 10.10 | 58.39 | 19.70 | 11.81 | 11.81 | 41.36 | 80.56 | 0.4983 | 1.64 | 8.60 | -- | 14.23 | 23.17 | 15.19 | 26.20 | 57.59 | 58.56 | 28.56 | 33.21 | 9.65 | 66.88 | 0.0307 | -- | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 81.71bn | 178.20m | 208.68bn | 6.72k | 3,114.95 | 2.64 | 27.52 | 2.55 | 0.0507 | 0.0507 | 64.88 | 59.80 | 0.5478 | 1.53 | 4.15 | 12,161,270.00 | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Pfizer Ltd | 21.93bn | 5.51bn | 211.65bn | 1.70k | 38.39 | 5.89 | 34.49 | 9.65 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 219.21bn | 3.98k | 15.83 | 3.74 | 13.92 | 5.48 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 257.24bn | 6.01k | 160.50 | 6.26 | 46.54 | 5.10 | 2.97 | 2.97 | 93.32 | 76.27 | 0.6282 | 1.38 | 3.11 | 8,391,593.00 | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 47.63 | 3.34 | 12.83 | 0.6393 | 2.22 | 0.3851 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 270.47bn | 5.10k | 49.60 | 9.25 | 39.14 | 7.76 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 283.07bn | 7.84k | 34.98 | 8.00 | 29.75 | 6.73 | 64.79 | 64.79 | 334.10 | 283.31 | 0.9034 | 1.30 | 3.65 | 5,365,515.00 | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.22 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 77.07bn | 5.47bn | 302.61bn | 16.17k | 55.27 | 4.78 | 34.14 | 3.93 | 21.58 | 21.58 | 303.89 | 249.59 | 0.7814 | 1.22 | 5.76 | -- | 5.37 | 10.33 | 7.51 | 13.52 | 66.58 | 60.93 | 6.87 | 12.25 | 1.30 | 12.59 | 0.1569 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Gland Pharma Ltd | 56.65bn | 7.72bn | 303.10bn | 4.59k | 39.24 | 3.47 | 27.13 | 5.35 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Glenmark Pharmaceuticals Ltd | 118.13bn | -18.99bn | 377.61bn | 15.56k | -- | 4.81 | -- | 3.20 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 430.09bn | 3.21k | 72.91 | 24.19 | 65.20 | 12.45 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Data as of Jul 05 2024. Currency figures normalised to IPCA Laboratories Ltd's reporting currency: Indian Rupee INR
30.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 May 2024 | 20.90m | 8.24% |
| DSP Asset Managers Pvt. Ltd.as of 15 Jun 2024 | 16.80m | 6.62% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 May 2024 | 11.29m | 4.45% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 5.16m | 2.03% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 May 2024 | 4.67m | 1.84% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2024 | 4.60m | 1.81% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Apr 2024 | 4.41m | 1.74% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 May 2024 | 3.77m | 1.49% |
| PPFAS Asset Management Private Ltd.as of 31 May 2024 | 3.72m | 1.47% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 3.27m | 1.29% |
More ▼
Data from 31 Mar 2024 - 04 Jul 2024Source: FactSet Research Systems Inc.
